Asxl1loss Cooperates with Oncogenic Nras in Mice to Reprogram Immune Microenvironment and Drive Leukemic Transformation

0
152
Investigators showed that concurrent ASXL1 and NRAS mutations defined a population of chronic myelomonocytic leukemia patients with shorter leukemia-free survival than those with ASXL1 mutation only.
[Blood]
Abstract